Ενημερώσεις: EASD-ADA, EASD-ISPAD Statements 2020
Glucose Management for Exercise using Continuous Glucose Monitoring (CGM) and Intermittently Scanned CGM (isCGM) Systems inType 1 Diabetes – Position Statement of the European Association for the Study of Diabetes (EASD)and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) – 2020 download ➥
Physical exercise is an important component in the management of type 1 diabetes across the lifespan. Yet, acute exercise increases the risk of dysglycaemia,and the direction of glycaemic excursions depends to some extenton the intensity and duration of the type of exercise. Understandably, fear of hypoglycaemia is one of the strongest barriers to incorporate exercise in daily life. Risk of hypoglycaemia during and after exercise can be lowered when insulin dose adjustments are made and/or additional carbohydrates are consumed. Glycaemic management during exercise has been made easier with continuous (CGM) and intermittently scanned glucose monitoring (isCGM) systems; however, because of the complexity of CGM and isCGM systems, both individuals with type 1 diabetes and their health care professionals may struggle with the interpretation of given information to maximise the technological potential for effective use around exercise. This position statement highlights the recent advancements in CGM and isCGM technology, with focus on the evidence base for their efficacy to sense glucose around exercise, adaptations in the use of these emerging tools,and updates the guidance for exercise in adults, children and adolescents with type 1 diabetes.
Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) – 2020 download ➥
The convergence of advances in medical science, human biology, data science and technology has enabled the generation of new insights into the phenotype known as ‘diabetes’. Increased knowledge of this condition has emerged from populations around the world, illuminating the differences in how diabetes presents, its variable prevalence and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes
Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the Study of Diabetes (EASD), including its mission, the current state of the field and prospects for the future. Expert opinions are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment) and key barriers to and opportunities for implementation of precision diabetes medicine, with better care and outcomes around the
globe, are highlighted. Cases where precision diagnosis is already feasible and effective (i.e. monogenic forms of diabetes) are presented, while the major hurdles to the global implementation of precision diagnosis of complex forms of diabetes are discussed. The situation is similar for precision therapeutics, in which the appropriate therapy will often change over time owing to the manner in which diabetes evolves within individual patients. This Consensus Report describes a
foundation for precision diabetes medicine, while highlighting what remains to be done to realise its potential. This, combined with a subsequent, detailed evidence-based review (due 2022), will provide a roadmap for precision medicine in diabetes that helps improve the quality of life for all those with diabetes.
Επιμέλεια: Σπύρος Καραμαγκιώλης, Ειδικός Παθολόγος - Διαβητολόγος